Context Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on development of medicines and novel therapies for the treatment of female cancer patients. Context Therapeutics serves customers in the United States.

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-07-09)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Context Therapeutics (CNTX US)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-07-09)

Current Report (Form 8-K | Period ending 2024-06-13)

424B3 | Prospectus

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)